We are live on ! Find out more
FLNA

Filana Therapeutics
FLNA

44 hedge funds and large institutions have $57.5M invested in Filana Therapeutics in 2016 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 13 increasing their positions, 13 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

28% more capital invested

Capital invested by funds: $44.8M → $57.5M (+$12.7M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 13

10% less funds holding

Funds holding: 49 → 44 (-5)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 5

Holders
44
Holders Change
-5
Holders Change %
-10.2%
% of All Funds
1.17%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
–
Increased
13
Reduced
13
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NCM
Nantahala Capital Management
Connecticut
+$1.15M
2
BI
BVF Inc
California
+$550K
3
Renaissance Technologies
Renaissance Technologies
New York
+$100K
4
6CM
683 Capital Management
New York
+$46.2K
5
BIP
Brandes Investment Partners
California
+$36.2K

Top Sellers

Rank Fund Capital Flow
1
JGC
J. Goldman & Co
New York
-$789K
2
GIM
Granahan Investment Management
Massachusetts
-$90K
3
SCM
Stonepine Capital Management
Oregon
-$82.4K
4
VKH
Virtu KCG Holdings
New York
-$63K
5
Goldman Sachs
Goldman Sachs
New York
-$51K
Name Holding Trade Value Shares
Change 		Change in
Stake
Connor, Clark & Lunn Investment Management (CC&L)
26
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$80K -$1.84K -142 -3%
Bank of America
27
Bank of America
North Carolina
$62K – – –
Charles Schwab
28
Charles Schwab
California
$42K – – –
ARTA
29
A.R.T. Advisors
New York
$31K -$27.9K -2,157 -52%
Susquehanna International Group
30
Susquehanna International Group
Pennsylvania
$31K +$3.8K +294 +17%
Wells Fargo
31
Wells Fargo
California
$28K +$4.8K +371 +26%
Royal Bank of Canada
32
Royal Bank of Canada
Ontario, Canada
$22K – – –
BA
33
BlackRock Advisors
Delaware
$19K – – –
BIM
34
BlackRock Investment Management
Delaware
$15K – – –
TRCT
35
Tower Research Capital (TRC)
New York
$5K -$11.5K -886 -75%
Citigroup
36
Citigroup
New York
$3K – – –
Morgan Stanley
37
Morgan Stanley
New York
$2K -$40.2K -3,104 -96%
UBS Group
38
UBS Group
Switzerland
$2K -$4.8K -371 -74%
MFS
39
MSI Financial Services
Massachusetts
$2K – – –
TCOV
40
Trust Company of Vermont
Vermont
$1K – – –
Geode Capital Management
41
Geode Capital Management
Massachusetts
$453 -$323 -25 -0.1%
VKH
42
Virtu KCG Holdings
New York
– -$63K -5,158 Closed
Goldman Sachs
43
Goldman Sachs
New York
– -$51K -4,194 Closed
Millennium Management
44
Millennium Management
New York
– -$48K -3,917 Closed
TC
45
TFS Capital
Pennsylvania
– -$20K -1,643 Closed
PPA
46
Parametric Portfolio Associates
Washington
– -$18K -1,504 Closed
Deutsche Bank
47
Deutsche Bank
Germany
– -$8.31K -642 -98%
Simplex Trading
48
Simplex Trading
Illinois
– -$841 -65 -98%
1
2

FLNA Hedge Fund Activity: Q1 2016 in Review

44 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Filana Therapeutics (FLNA) for Q1 2016, worth a combined $57.5M — up 28% from $44.8M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of FLNA and 0 opened new positions — a net loss of 5 holders — while 13 trimmed existing stakes and 13 added.

The largest buyer was Nantahala Capital Management, adding an estimated $1.15M. The largest seller was J. Goldman & Co, cutting an estimated $789K.

  • 44 institutional investors held Filana Therapeutics (FLNA) as of Q1 2016, down from 49 in Q4 2015.
  • Funds reported $57.5M of Filana Therapeutics stock for Q1 2016, up 28% quarter-over-quarter.
  • 0 funds opened new Filana Therapeutics positions in Q1 2016 and 5 closed out, a net change of -5 holders.
  • The largest Filana Therapeutics buyer in Q1 2016 was Nantahala Capital Management, an estimated $1.15M added.
  • The largest Filana Therapeutics seller in Q1 2016 was J. Goldman & Co, an estimated $789K sold.

Based on aggregated 13F filings for Q1 2016.